.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Moodys
Novartis
Express Scripts
Argus Health
Federal Trade Commission
QuintilesIMS
Daiichi Sankyo
Chubb
Johnson and Johnson

Generated: November 18, 2017

DrugPatentWatch Database Preview

Claims for Patent: 5,665,772

« Back to Dashboard

Claims for Patent: 5,665,772

Title: O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
Abstract:Novel derivatives of rapamycin, particularly 9-deoxorapamycins, 26-dihydro-rapamycins, and 40-0-substituted and 28,40-0,0-di-substituted rapamycins, are found to have pharmaceutical utility, particularly as an immunosuppressants.
Inventor(s): Cottens; Sylvain (Witterswil, CH), Sedrani; Richard (Basel, CH)
Assignee: Sandoz Ltd. (Basel, CH)
Application Number:08/416,673
Patent Claims: 1. A compound of the formula ##STR3## wherein R.sup.1 is hydroxy(C.sub.1-6)alkyl or hydroxy(C.sub.1-3)alkoxy(C.sub.1-3)alkyl.

2. A compound according to claim 1 in which R.sup.1 is hydroxy(C.sub.1-3)alkyl or hydroxy(C.sub.1-3)alkoxy(C.sub.1-3)alkyl.

3. A compound according to claim 1 in which R.sup.1 is hydroxy(C.sub.1-3)alkyl.

4. A compound according to claim 1 in which R.sup.1 is hydroxy(C.sub.1-3)alkoxy(C.sub.1-3)alkyl.

5. The compound according to claim 1 which is 40-O-(3-hydroxypropyl)-rapamycin.

6. The compound according to claim 1 which is 40-O-[2-(2-hydroxyethoxy)ethyl]-rapamycin.

7. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier therefor.

8. A method of inducing an immunosuppressant effect in a subject in need of immunosuppression, which comprises administering to said subject an immunosuppressant effective amount of a compound according to claim 1.

9. A method of preventing allograft rejection in a subject in need of such treatment, which comprises administering to said subject a compound according to claim 1 in an amount effective to prevent allograph rejection.

10. The compound according to claim 1 which is 40-O-(3-hydroxyethyl)-rapamycin.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Citi
Johnson and Johnson
Express Scripts
Cipla
Chinese Patent Office
US Department of Justice
US Army
Merck
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot